BeiGene, Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
238.31
-3.12 (-1.29%)
At close: May 27, 2025, 4:00 PM
233.71
-4.60 (-1.93%)
After-hours: May 27, 2025, 4:08 PM EDT
BeiGene Revenue
BeiGene had revenue of 8.05B CNY in the quarter ending March 31, 2025, with 48.28% growth. This brings the company's revenue in the last twelve months to 30.34B, up 52.09% year-over-year. In the year 2024, BeiGene had annual revenue of 27.81B with 59.51% growth.
Revenue (ttm)
30.34B CNY
Revenue Growth
+52.09%
P/S Ratio
6.00
Revenue / Employee
2,757,959 CNY
Employees
11,000
Market Cap
28.21B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.81B | 10.38B | 59.51% |
Dec 31, 2023 | 17.43B | 7.67B | 78.53% |
Dec 31, 2022 | 9.77B | 2.29B | 30.69% |
Dec 31, 2021 | 7.47B | 5.46B | 270.56% |
Dec 31, 2020 | 2.02B | -965.08M | -32.37% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ONC News
- 15 hours ago - BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology - Business Wire
- 17 hours ago - BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer - Business Wire
- 5 days ago - BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors - Business Wire
- 13 days ago - BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation Innovation - Business Wire
- 14 days ago - BeiGene to Present at the RBC Capital Markets Global Healthcare Conference - Business Wire
- 15 days ago - Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices + - Seeking Alpha
- 19 days ago - BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit - Seeking Alpha
- 20 days ago - BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript - Seeking Alpha